Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Identifieur interne : 000686 ( Main/Corpus ); précédent : 000685; suivant : 000687Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Auteurs : ShoulsonSource :
- Annals of Neurology [ 0364-5134 ] ; 1998-03.
Abstract
Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.
Url:
DOI: 10.1002/ana.410430309
Links to Exploration step
ISTEX:D6EC36101AD108D1D7DFCF08DE1598F05817AD1FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D6EC36101AD108D1D7DFCF08DE1598F05817AD1F</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/ana.410430309</idno><idno type="url">https://api.istex.fr/document/D6EC36101AD108D1D7DFCF08DE1598F05817AD1F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000686</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-03">1998-03</date><biblScope unit="volume">43</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="318">318</biblScope><biblScope unit="page" to="325">325</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">D6EC36101AD108D1D7DFCF08DE1598F05817AD1F</idno><idno type="DOI">10.1002/ana.410430309</idno><idno type="ArticleID">ANA410430309</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr Shoulson</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</json:string></affiliations></json:item></author><articleId><json:string>ANA410430309</json:string></articleId><language><json:string>eng</json:string></language><abstract>Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.</abstract><qualityIndicators><score>7.204</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1377</abstractCharCount><pdfWordCount>4804</pdfWordCount><pdfCharCount>30167</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>200</abstractWordCount></qualityIndicators><title>Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title><corporate><json:item><name>Parkinson Study Group</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>43</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>8</total><last>325</last><first>318</first></pages><issn><json:string>0364-5134</json:string></issn><issue>3</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/ana.410430309</json:string></doi><id>D6EC36101AD108D1D7DFCF08DE1598F05817AD1F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D6EC36101AD108D1D7DFCF08DE1598F05817AD1F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D6EC36101AD108D1D7DFCF08DE1598F05817AD1F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D6EC36101AD108D1D7DFCF08DE1598F05817AD1F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title><author><orgName>Parkinson Study Group</orgName></author><author><persName><surname>Shoulson</surname></persName><roleName type="degree">Dr</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</p></note><affiliation>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-03"></date><biblScope unit="volume">43</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="318">318</biblScope><biblScope unit="page" to="325">325</biblScope></imprint></monogr><idno type="istex">D6EC36101AD108D1D7DFCF08DE1598F05817AD1F</idno><idno type="DOI">10.1002/ana.410430309</idno><idno type="ArticleID">ANA410430309</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1997-07-08">Received</change><change when="1997-10-17">Registration</change><change when="1998-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D6EC36101AD108D1D7DFCF08DE1598F05817AD1F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/ana.v43:3</doi><numberingGroup><numbering type="journalVolume" number="43">43</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1998-03">March 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410430309</doi><idGroup><id type="unit" value="ANA410430309"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Orignal Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1998 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="1997-07-08"></event><event type="manuscriptRevised" date="1997-10-17"></event><event type="manuscriptAccepted" date="1997-10-17"></event><event type="firstOnline" date="2004-10-08"></event><event type="publishedOnlineFinalForm" date="2004-10-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">318</numbering><numbering type="pageLast">325</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410430309.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="5"></count><count type="referenceTotal" number="20"></count></countGroup><titleGroup><title type="main" xml:lang="en">Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title><title type="short" xml:lang="en">Mortality in DATATOP</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" corresponding="yes" affiliationRef="#corr1"><personName><honorifics>Dr</honorifics><familyName>Shoulson</familyName></personName></creator><creator xml:id="au2" creatorRole="author" noteRef="#fn1"><groupName>Parkinson Study Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="corr1"><unparsedAffiliation>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>See the appendix on page 324 for a complete listing of authors</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Mortality in DATATOP</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Mortality in DATATOP: A Multicenter trial in early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Shoulson</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</affiliation><description>Correspondence: Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</description><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>Parkinson Study Group</namePart><description>Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-03</dateIssued><dateCaptured encoding="w3cdtf">1997-07-08</dateCaptured><dateValid encoding="w3cdtf">1997-10-17</dateValid><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">5</extent><extent unit="references">20</extent></physicalDescription><abstract lang="en">Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>318</start><end>325</end><total>8</total></extent></part></relatedItem><identifier type="istex">D6EC36101AD108D1D7DFCF08DE1598F05817AD1F</identifier><identifier type="DOI">10.1002/ana.410430309</identifier><identifier type="ArticleID">ANA410430309</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000686 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000686 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D6EC36101AD108D1D7DFCF08DE1598F05817AD1F
|texte= Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |